[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"uterine-fibroids-uf\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:uterine-fibroids-uf":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,82,112,136,169,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100569291","hifu-versus-myomectomy-for-the-treatment-of-symptomatic-uterine-fibroids-100569291",false,"NCT06692335","HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids","A Randomized Controlled Trial of High-Intensity Focused Ultrasound (HIFU) Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids","Inclusion Criteria:\n\n* Age 18 - 50 years-old\n* Pre or peri menopausal with FSH less than 25 mIU\u002Fml\n* BMI \\\u003C 33 kg\u002Fm2 or abdominal wall thickness \\\u003C 5 cm\n* Uterine size ≤18 weeks based on physical exam assessment\n* Dominant intramural fibroid ≥ 3cm and ≤ 10cm on imaging\n* Symptomatic fibroids cause menorrhagia, pressure, or pelvic pain\n* Willing and able to give informed consent\n\nExclusion Criteria:\n\n* Patient with other pelvic mass indicated by history or magnetic resonance imaging (MRI) such as endometriosis, abnormal adnexal mass, ovarian tumor, acute or chronic pelvic inflammatory disease\n* Morbid obesity\n* Inability to lie in a prone position for more than 2 hours\n* Extensive abdominal scar on the acoustic channel\n* Women with pregnancy, lactation or menopause\n* Uterine premalignant or malignant pathologies or pathology other than uterine fibroid cannot be ruled out through detailed clinical assessment and investigation including MRI\n* Rapid growth of fibroids, defined as a doubling in size in 6 months\n* History of or current thromboembolic event (deep vein thrombosis, pulmonary embolus, stroke)\n* Coagulation problem or using medication which affect clotting function\n* History of pelvic irradiation\n* Pedunculated submucosal or subserosal fibroid of size ≧5cm and with a stalk less than 25% of the maximal fibroid diameter\n* Cervical\u002F broad ligament fibroid\n* Contraindication to MRI due to severe claustrophobia or implanted metallic device.\n* Co-existing adenomyosis","FEMALE","18 Years","50 Years",{"count":20,"type":21},112,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if High-Intensity Focused Ultrasound (HIFU) is as effective as myomectomy for treating symptomatic uterine fibroids in women aged 18 to 50. The main questions it aims to answer are:\n\nIs HIFU as effective as myomectomy in improving quality of life for women with uterine fibroids? How do the recovery times and complications compare between HIFU and myomectomy? Researchers will compare the outcomes of women receiving HIFU treatment to those undergoing myomectomy to see if HIFU offers similar or better results with fewer complications.\n\nParticipants will:\n\nUndergo an initial medical assessment, including ultrasounds and blood tests. Receive either HIFU treatment or myomectomy based on random assignment. Complete questionnaires about their symptoms and quality of life before treatment and at follow-up visits (3 and 6 months post-treatment).\n\nBe monitored for any complications and recovery progress during follow-up.",[27],"Uterine Fibroids (UF)",[29,30,31],"symptomatic uterine fibroid","Menorrhagia","Dysmenorrhea","RECRUITING","2026-03-26",{"date":35,"type":36},"2026-03-27","ACTUAL",{"date":38,"type":36},"2025-02-06",{"date":40,"type":21},"2027-12-31",{"name":42,"class":43},"Chinese University of Hong Kong","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":63,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":44},"100631514","transmucosal-uterosacral-electrical-stimulation-for-pelvic-pain-relief-100631514","NCT07501676","Transmucosal Uterosacral Electrical Stimulation for Pelvic Pain Relief","TUNES","Inclusion Criteria:\n\n* Female, 28-52 years of age\n* Scheduled to undergo uterine fibroid embolization (UFE) at Weill Cornell Medicine\n* Able to provide informed consent\n* Willing to comply with all study procedures and follow-up\n* Fluent in English (for completion of study assessments)\n\nExclusion Criteria:\n\n* Known or suspected pregnancy\n* Active pelvic infection\n* History of pelvic inflammatory disease within the past 6 months\n* Implanted electrical device (e.g., pacemaker, neurostimulator)\n* Current use of opioid pain medication prior to procedure\n* History of chronic pelvic pain not related to fibroids\n* Known allergy or sensitivity to medical-grade silicone\n* Participation in another interventional study within 30 days","28 Years","52 Years",{"count":55,"type":21},60,[24],"This study will test whether gentle electrical stimulation to nerves near the uterus can reduce pelvic pain after uterine fibroid embolization. The investigators hypothesize that participants receiving active TUNES stimulation will experience lower pain levels and improved early recovery compared to those receiving sham stimulation or standard care.",[59,27,60,61,62],"Postoperative Pain After Uterine Fibroid Embolization","Uterine Fibroids","Pelvic Pain","Pain Management",[64,50,65,66,67,68,69,70,71],"Transmucosal Uterosacral Electrical Stimulation","Uterine Fibroid Embolization","UFE","Post-UFE Pain","Electrical Stimulation Therapy","Pelvic Pain Relief","Noninvasive Neuromodulation","Weill Cornell Medicine","NOT_YET_RECRUITING","2026-03-24",{"date":75,"type":36},"2026-03-30",{"date":77,"type":21},"2026-04-01",{"date":79,"type":21},"2026-09-30",{"name":81,"class":43},"Weill Medical College of Cornell University",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":93,"studyType":94,"phases":4,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":44},"100610658","artificial-intelligence-for-the-intra-procedural-assessment-of-uterine-artery-embolization-100610658","NCT07230444","Artificial Intelligence for the Intra-procedural Assessment of Uterine Artery Embolization","Validation and Implementation With Artificial Intelligence of Software for the Intra-procedural Assessment of Uterine Artery EMBOlization","AI-EMBO","Inclusion Criteria:\n\n* Female patients ≥18 years\n* Symptomatic uterine fibroids (e.g., bleeding, bulk symptoms, pain)\n* Underwent UAE as definitive therapy\n* Availability of baseline clinical\u002Fimaging data (for retrospective arm) or ability to provide informed consent (for prospective arm)\n\nExclusion Criteria:\n\n* Lack of clinical follow-up\n* Poor quality or incomplete angiographic images.","55 Years",{"count":92,"type":21},250,"6 Months","OBSERVATIONAL","Uterine artery embolization is a minimally invasive treatment for symptomatic uterine fibroids, but intra-procedural assessment of embolization adequacy currently relies on subjective angiographic criteria. This study evaluates a proprietary angiographic analysis software (AQ-VERO) that extracts quantitative time-to-density perfusion metrics in real time. The study aims to (1) validate the accuracy and reproducibility of AQ-VERO during uterine artery mebolization, and (2) develop an AI-based decision support system using AQ-VERO-derived metrics to improve objective intra-procedural assessment of treatment endpoints.",[27],[98,99,100,101,102],"uterine fibroids","embolization","uterine artery embolization","quantitative imaging","artificial intelligence","2025-11-15",{"date":105,"type":36},"2025-11-19",{"date":107,"type":21},"2025-12-01",{"date":109,"type":21},"2027-05-31",{"name":111,"class":43},"Emanuele Barabino",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":44},"100567082","comparing-the-efficacy-of-tu-less-and-vnotes-for-hysterectomy-of-enlarged-uterus-100567082","NCT06663553","Comparing the Efficacy of TU-LESS and vNOTES for Hysterectomy of Enlarged Uterus","Protocol for a Comparative Study of the Efficacy of Transumbilical Laparoendoscopic Single-site Surgery (TU-LESS) and Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) in Hysterectomy Performed on Patients With Enlarged Uterus: A Prospective Single-blinded, Randomized Clinical Trial","Inclusion Criteria:\n\n* Eligible women aged 18-70 years.\n* Women with indications for enlarged uterine volumes who are planning to under go total hysterectomy. Uterine size should exceed that of a 3-month pregnancy (uterine weight ≥ 280 g).\n* Patients are willing to be randomly assigned to undergo any of both approaches.\n* Patients who are willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Individuals who are virgins or have vaginal stenosis.\n* Patients requiring concurrent surgical intervention for conditions such as ovarian cysts or lesions of the vulva, vagina, appendix, etc.\n* presence of uterus exceeding approximately 20 gestational weeks in size (about 900-1000g), which is beyond the limitations of a single-site laparoscopic approach due to concerns regarding technical feasibility and safety\n* Presence of malignancy or strong suspicion of malignancy that may alter the planned surgical approach.\n* History of two or more pelvic surgeries or suspected severe pelvic adhesions (rectovaginal examination suggesting rectovaginal endometriosis or limited uterine mobility).\n* History of peritoneal dialysis, pelvic radiation therapy and pelvic tuberculosis treated with laparoscopic surgery.\n* Patients with prolapse or pelvic inflammation.\n* Diabetes mellitus with poor blood glucose control.\n* Body mass index greater than 30 kg\u002Fm².","70 Years",{"count":121,"type":21},210,[24],"Enlarged uterus is frequently encountered in clinical practice, and its incidence due to conditions such as adenomyosis, uterine fibroids, and other gynecological disorders has steadily increased over the years statistically. For example, greater healthcare awareness has led to more frequent early diagnoses of these conditions, contributing to the observed rise in incidence. Additionally, increasing life expectancy results in more women reaching the perimenopausal and postmenopausal stages, during which conditions like uterine fibroids and adenomyosis become more prevalent. For these women, hysterectomy (removal of the entire uterus) is often the recommended option of treatment.\n\nWith advances in surgical techniques over recent decades, there has been a notable shift from traditional open abdominal surgeries to minimally invasive approaches. Laparoscopic surgery has been widely adopted, significantly reducing the size and number of incisions required, thereby promoting faster recovery, minimizing postoperative pain, and reducing the risk of complications.\n\nHowever, conventional multi-port laparoscopic hysterectomy still presents certain challenges, such as large uterus extraction following resection, and concerns about healing of incisions. In contrast, innovative techniques like Transumbilical Laparoendoscopic Single-Site Surgery(TU-LESS) and Transvaginal Natural Orifice Transluminal Endoscopic Surgery(vNOTES) both take advantage of natural anatomical openings to achieve minimal or no visible scarring. Studies demonstrate that these techniques provide superior outcomes in terms of reduced pain, faster recovery, and quicker return to daily activities compared to traditional multi-port laparoscopic approaches.\n\nYet a direct comparison of the efficacy of these two methods in real-world, particularly for enlarged uterus, remains inconclusive. Thus this study aims to evaluate and compare the outcomes of these two techniques in patients with enlarged uteri. Participants will be randomly assigned to receive one of the two surgical approaches, ensuring an unbiased comparison of the efficacy of the procedures in terms of healing status and recovery time.",[125,126,27],"Enlarged Uterus","Adenomyosis","2025-09-16",{"date":129,"type":36},"2025-09-18",{"date":131,"type":21},"2025-10-01",{"date":133,"type":21},"2028-10",{"name":135,"class":43},"West China Second University Hospital",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":144,"enrollmentInfo":145,"targetDuration":147,"studyType":94,"phases":4,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100603498","popq-associated-with-total-laparoscopic-hysterectomy-100603498","NCT07137299","POPQ Associated With Total Laparoscopic Hysterectomy","POPQ Associated With Total Laparoscopic Hysterectomy - Multicenter Prospective Observational Study - POP-LAP STUDY","POP-LAP","Inclusion Criteria:\n\n* persons who underwent total or subtotal hysterectomy for benign conditions regardless of the type of surgery\n* agree to participate and to follow-up\n\nExclusion Criteria:\n\n* having uterus\n* health state - ECOG \\>2\n* pelvic organ prolapse prior to the surgery\n* surgery due to malignant conditions (ovarian, cervical or endometrial cancer)","85 Years",{"count":146,"type":21},2000,"10 Years","The goal of this observational study is to evaluate the impact of different hysterectomy (removal of the uterus) techniques on the risk of pelvic organ prolapse (situation when one or more of your pelvic organs like your bladder, uterus, or rectum have dropped down or slipped out of their normal position, sometimes even bulging into the vagina) and urinary incontinence (leaking urine unexpectedly) in women aged 18-85 who underwent hysterectomy or supracervical hysterectomy (removing of the uterus without its cervix) for benign (not cancer) conditions.\n\nThe main question is: to check how different surgical technique (laparoscopic, with opening the abdomen, vaginal and robotic) increase the risk of pelvic organ prolapse or urinary incontinence There is no randomization or control group; comparisons will be made between surgery types based on clinical and questionnaire data.\n\nParticipants will:\n\n* Receive an invitation to participate if they underwent hysterectomy between 2021-2025.\n* Fill out validated quality of life questionnaires (P-QOL, POPDI-6, PFIQ-7) every two years.\n* Attend follow-up clinical pelvic exams every two years to assess vaginal cuff healing, pelvic organ prolapses (POP-Q system), and urinary symptoms.\n\nThis prospective, non-commercial, multicenter study plans to enroll 2,000 women and will run from July 1, 2025, to July 1, 2036",[27,150,151,152],"Abnormal Uterine Bleeding Unrelated to Menstrual Cycle","Endometrial Hyperplasia","Pelvic Organ Prolapse (POP)",[154,155,156,157,158,159],"Hysterectomy","Vaginal hysterectomy","Laparotomy","Laparoscopy","Robotic surgery","pelvic organ prolapse","2025-08-15",{"date":162,"type":36},"2025-08-22",{"date":131,"type":21},{"date":165,"type":21},"2037-07-01",{"name":167,"class":43},"Medical University of Silesia",4,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":176,"targetDuration":4,"studyType":22,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":44},"100581105","anatomopathological-evaluation-of-a-new-ultrasound-guided-transuterine-vaginal-biopsy-technique-in-uterine-fibromatous-disease-100581105","NCT06845982","Anatomopathological Evaluation of a New Ultrasound-guided Transuterine Vaginal Biopsy Technique in Uterine Fibromatous Disease","EFIBIA","Inclusion Criteria:\n\n* Patients over 18 years of age consulting the CHU de la Conception who require surgical treatment for uterine smooth muscle tumours (fibroma or TMM).\n* Able to give written consent\n* Beneficiary or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Person in a period of exclusion from another research protocol at the time of signing consent\u002Fno objection\n* Subjects covered by articles L1121-5 to 1121-8 of the Public Health Code, i.e. :\n* Pregnant women, women in labour and nursing mothers\n* Persons deprived of their liberty by judicial or administrative decision\n* Persons subject to psychiatric monitoring under articles L3112-1 and L3113-1 who are not covered by the provisions of article L1121-8\n* Minors\n* Adults subject to a legal protection measure or unable to express their consent.\n* A person who does not have a sufficient command of reading and understanding the French language to be able to consent to participate in the research.\n* Any other reason which, in the opinion of the investigator, could compromise the safety of the research participant and\u002For interfere with the evaluation of the objectives of the research.",{"count":92,"type":21},[24],"The benign uterine fibroid is part of the broader term uterine smooth muscle tumour, which also includes malignant myometrial tumours (MSTs) of varying malignancy (uterine sarcoma, cellular fibroid, STUMP (uterine smooth muscle tumours of uncertain malignant potential)).\n\nMagnetic resonance imaging (MRI) is the most effective test for distinguishing a fibroid from a TMM, but its reliability is limited. This leads to inappropriate management in a number of situations. The first is the risk of overtreatment by performing surgery for a suspected TMM on MRI in a patient with few or no symptoms and a final histological diagnosis of fibroid. The second is the risk of unsatisfactory or even harmful cancer surgical treatment in a symptomatic patient with a reassuring MRI diagnosis but a final histological diagnosis of TMM. Finally, there is the possibility of treating a lesion labelled as a fibroid on MRI with an alternative technique (embolisation, radiofrequency, HIFU) when it is in fact a TMM, thereby delaying appropriate treatment and worsening the prognosis.\n\nUltrasound-guided transuterine vaginal biopsy (ETVB) is an innovative and promising minimally invasive technique for preoperative anatomopathological diagnosis. It would make it possible to obtain a histological diagnosis without the need for surgery, thereby avoiding the inappropriate management described above.\n\nThe aim of this study is to validate an innovative minimally invasive surgical technique (BVTE) for the diagnosis of uterine smooth muscle tumours by biopsy, to assess the complications associated with the technique and any potential adverse effects, and to evaluate the feasibility of the technique in current practice.",[27],"2025-02-20",{"date":182,"type":36},"2025-02-25",{"date":184,"type":21},"2025-03-01",{"date":186,"type":21},"2028-10-01",{"name":188,"class":43},"Assistance Publique Hopitaux De Marseille",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":16,"minAge":196,"maxAge":197,"enrollmentInfo":198,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100565327","phase-4-investigating-the-optimal-remifentanil-and-dexmedetomidine-concentration-for-uterine-fibroid-ablation-100565327","NCT06640738","Investigating the Optimal Remifentanil and Dexmedetomidine Concentration for Uterine Fibroid Ablation","Remifentanil and Dexmedetomidine in Uterine Fibroid Ablation: a Comparative Study","Inclusion Criteria:\n\n* Aged between 20 and 65 years old\n* American Society of Anesthesiology classification I\\~III\n* Female patients diagnosed with uterine fibroids by obstetricians and gynecologists\n\nExclusion Criteria:\n\n1. Patients with heart disease (such as arrhythmia or severe ventricular dysfunction)\n2. Patients with chronic kidney disease in stage III or above or dialysis patients\n3. Long-term alcohol addiction or drug abuse\n4. Patients with abnormal liver index or chronic hepatitis\n5. Those who are allergic Remifentanil\n6. Those who refuse to participate in the experiment","20 Years","65 Years",{"count":55,"type":21},[200],"PHASE4","This clinical trial aims to find a better drug concentration of Remifentanil in Uterine Fibroid Ablation. The main question it seeks to answer is:\n\n\\[primary hypothesis 1\\] Remifentanil concentration of 2.0 ng\u002FmL provides better pain control in Uterine Fibroid Ablation.\n\nThere is a comparison group in this study: Researchers will compare Remifentanil concentration of 1.0 ng\u002FmL to see if provides similar pain control with fewer side effects.\n\nParticipants will be separated into two groups, one group with a Remifentanil concentration of 2.0 ng\u002FmL and the other 1.0 ng\u002FmL. During uterine fibroid ablation, the patient\\'s pain index will be recorded (using a Visual Analogue Scale (VAS) of 0\\~10 points). We will also record vital signs during the procedure.",[27],[27,204],"Remifentanil","2024-10-11",{"date":207,"type":36},"2024-10-15",{"date":209,"type":21},"2024-10-01",{"date":211,"type":21},"2026-10-31",{"name":213,"class":43},"Kaohsiung Medical University"]